Agile Therapeutics, Inc

AGRX NASDAQ

Joshh_Tradess

Butterfly harmonic w/ a dragon pattern along a horizontal support and a historical reversal area. Daily MACD and RSI classic bullish divergence. Stop = Below reversal area (Look for a close below reversal area). 1st Target = 3/1 R/R 2nd Target = 0.236 fib extension 3rd Target = Resistance / 'B' of butterfly harmonic.

traderken0819

Signals: Terminal flag in Trading range - 3 bottom Buy Divergence on decreasing supply & Increasing demand. Four Month Non Climactic accumulation pattern Entry 2.83 1st target $3 2nd Target $3.25-3.30 3rd Target Retest of 52W Highs Stop Loss- $2.75 **May re-enter on Buy Stop above $3 if stopped out

Weedkiller420

This chart looks bullish to me having tested the 200 MA 3x and bouncing off to close above the 78.6% fib level. I think 2.94 will be established as support and the stock will rise up the Fibonacci scale $3.14 is my short-term target. *disclosure: I have no idea what their earnings will be. My opinion is based on the chart alone.

tradingbulls2

High risk= High reward, to be added on russel on june 29- load 2.5c sep

madafakaa

A pullback to 2.77 then a bounce is my expectation.

KozakHlib

Contextual immersion trading strategy idea. Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. The demand for shares of the company looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I...

MrMercato

Please note: just sharing my view. its not a recommendation for buying or selling

ahudson1

Crossed upper Bollinger Band, and it continued uptrend while testing moving average support levels. I can see it reaching $3.30-$3.50 range in the next 3-5 days.

PennyStock101

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

PennyStock101

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

cryptorichhh

Take profit 1: 7.50 Take profit 2: 10.00 FDA decision on the companies product Twirla. Womans contraceptive patch BRUDAC ADcomm voted 14-1 in favor. 200mmil marketcap with a 4bill addressable market. Chasing approval since 2013. Approval IS NOT for certain. They could be issued a CRL. Could go much higher on approval. Manage your risk accordingly.

ReversalJerk

• Ticker - AGRX • Entry: 2.93 • Stop loss: 2.74 • Profit target 1: 3.12 • Profit target 2: 3.21

jayce.nugent

This cash strapped company will dilute its shares sooner than later in order to keep itself going. Right now the price is high and at resistance... An opportune time to short !

Charlestrad3r

AGRX - Agile Therapeutics, Inc. The biotech/heathcare hedge fun PERCEPTIVE ADVISORS LLC has been increasing their stake in the company and currently owns 11,919,925 shares and that ranks AGRX the 34 largest holding. TWIRLA - 30 October Advisory committee meeting voted 14-1 in favor PDUFA is due the 16 FEB AGRX will Present at the 38th Annual J.P. Morgan...

JusWes

Congrats to those who bought the wedge on this from my last chart, profit made.

JusWes

Looks like it could bounce from this wedge, if it breaks the wedge, there could be a good run.

a1mtarabichi

Volume confirming a C&H formation with exit points set at numbers below (respectively) and stop loss at $1.28 & set for a parabolic week moving forward. TP1: $1.525 TP2: $1.68 Stop @ $1.28 -@a1mTarabichi Disclaimer Not financial advise. Please trade carefully & responsibly.

PennyStock101

Agile Therapeutics has resubmitted its U.S. marketing application for contraceptive patch Twirla, this follows the company receiving a CRL in December 2017 citing the need for additional adhesion data. Keep this on the watch-list for today and they weeks to come. When this moves it will be fast and frantic. Analyst Rating Overweight. 3 Buy 2 Hold Agile...